ASX-listed respiratory app technology developer ResApp is in the early stages of planning a randomised control trial of its new app-based diagnostic screening tool for COVID-19, following early results showing it had high sensitivity and good specificity.

The early clinical results showed it has potential use as a mass screening test prior to rapid antigen or polymerase chain reaction testing to rule out COVID-19.